Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Azelastine · Astepro, Optivar

Small molecule · developed by Rising

Approved FDA, May 2000
2 Registered trials

What is Azelastine?

Azelastine is a nasal spray formulation of azelastine hydrochloride, given at 137 µg twice daily in each nostril in combination with fluticasone propionate. It is studied in seasonal allergic rhinitis and allergic rhinitis due to allergens.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Astepro, Optivar
Drug type
Small molecule
Therapy area
Ear, nose & throat, Respiratory
Developer
Rising
In trials of
LGND, VTRS
FDA status
Approved as Astepro, Optivar (May 22, 2000), NDA021127

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07597473 Phase 4 Allergic Rhinitis Due to Allergens Completed VTRS
NCT00940953 Phase 2 Seasonal Allergic Rhinitis Completed LGND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic Rhinitis Due to AllergensSeasonal Allergic Rhinitis

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.